Angiotech announces results for the fourth quarter ended Decembe...( from any future results events or dev...)

from any future results, events or developments expressed or implied by

such forward-looking statements. Many such risks, uncertainties and other

factors are taken into account as part of our assumptions underlying

these forward-looking statements and include, among others, the

following: general economic and business conditions, both nationally and

in the regions in which we operate; market demand; technological changes

that could impact our existing products or our ability to develop and

commercialize future products; competition; existing governmental

regulations and changes in, or the failure to comply with, governmental

regulations; adverse results or unexpected delays in drug discovery and

clinical development processes; decisions, and the timing of decisions,

made by health regulatory agencies regarding approval of our technology

and products; the requirement for substantial funding to conduct research

and development and to expand commercialization activities or consummate

acquisitions; sales numbers and future guidance publicly provided by

Boston Scientific Corporation regarding sales of their paclitaxel-eluting

coronary stent products; and any other factors that may affect

performance. In addition, our business is subject to certain operating

risks that may cause the actual results expressed or implied by the

forward-looking statements in this report to differ materially from our

actual results. These operating risks include: our ability to attract and

retain qualified personnel; our ability to successfully complete

preclinical and clinical development of our products; changes in business

strategy or development plans; our failure to obtain patent protection

for discoveries; loss of patent protection resulting from third party

challenges to our patents; commercialization limitations imposed by

paten
'/>"/>